The efficacy and safety evaluation of immunochemotherapy with R-MAD in newly-diagnosed primary central nervous system lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16009117

Enrollment

Unknown

Registered

2016-08-29

Start date

2016-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

treatment group:rituximab

control group:none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. After comprehensive stage evaluation (brain and spine MRI, chest/abdomen/pelvis CT, slit lamp eye exam, CSF),lymphomas located in the brain, spinal cord, intraocular structures, cranial nerve and/or leptomeninges, no evidence of extra-CNS involvement; 2. The diagonosis was proven to be diffuse large B cell lymphoma by pathological histomorphology and immunohistochemistry; 3. At least have an objective evaluation of lesions; 4. Aged 18 to 85 years; male or female; KPS=40. 5. After diagonosis, they did not receive chemotherapy and/or radiatherapy; 6. Blood or urine pregnancy test negative in women with childbearing potential.

Exclusion criteria

Exclusion criteria: 1. Concomitant malignancy; 2. Evidence of extra-CNS involvement after staging workup; 3. pregnancy or breastfeeding; 4. Immunosuppression inclusing active infection, active hepatitis b infection or positive HIV serology.

Design outcomes

Primary

Measure	Time frame
complete remission rate;	—

Secondary

Measure	Time frame
overall survival;progression-free survival;	—

Countries

China

Contacts

Public ContactYuanbo Liu

Beijing Tiantan Hospital, Capital Medical University

yuanbol@ccmu.edu.cn+86 18801316916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026